Lexaria Bioscience (LEXX) Return on Sales (2017 - 2026)

Lexaria Bioscience has disclosed Return on Sales across 10 years of filings, most recently posting 0.73% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.73%, down 57.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 0.26% (down 8.0% YoY), and the FY2025 annual result was 0.17%, down 4.0% from the prior year.
• Return on Sales came in at 0.73% for Q1 2026 at Lexaria Bioscience, down from 0.21% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.05% in Q1 2024 to a low of 0.73% in Q1 2026.
• The 5-year median for Return on Sales is 0.21% (2024), against an average of 0.26%.
• Across the five-year window, Return on Sales jumped 127 bps in 2022 and tumbled 57 bps in 2026, its largest moves.
• Lexaria Bioscience's Return on Sales stood at 0.17% in 2022, then surged by 57 bps to 0.07% in 2023, then slumped by 96 bps to 0.15% in 2024, then plunged by 41 bps to 0.21% in 2025, then plunged by 252 bps to 0.73% in 2026.
• The last three Return on Sales figures came in at 0.73% (Q1 2026), 0.21% (Q4 2025), and 0.15% (Q3 2025), per Business Quant data.